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Review

AIDS and associated malignancies
Charles Wood1,* and William Harrington, Jr.2
1Nebraska

Center for Virology & School of Biological Sciences,
University of Nebraska, Lincoln, NE 68588, USA (*cwood1@unl.edu)
2 Sylvester Cancer Center, University of Miami, Miami, FL 33136, USA
Abstract
AIDS associated malignancies (ARL) is a major complication associated with AIDS patients upon immunosuppression. Chronically immunocompromised patients have a markedly increased risk of developing lymphoproliferative
disease. In the era of potent antiretrovirals therapy (ARV), the malignant complications due to HIV-1 infection have
decreased in developed nations where ARV is administered, but still poses a major problem in developing countries
where HIV-l incidence is high and ARV is still not yet widely available. Even in ARV treated individuals there is a concern that the prolonged survival of many HIV-l carriers is likely to eventually result in an increased number of malignancies diagnosed. Malignancies that were found to have high incidence in HIV-infected individuals are Kaposi’s sarcoma (KS), Hodgkin’sdisease (HD) and non-Hodgkin’s lymphoma (NHL). The incidence of NHL has increased nearly
200 fold in HIV-positive patients, and accounts for a greater percentage of AIDS defining illness in the US and Europe
since the advent of HAART therapy. These AIDS related lymphomas are distinct from their counterparts seen in HIV-l
seronegative patients. For example nearly half of all cases of ARL are associated with the presence of a gamma herpesvirus, Epstein Barr virus (EBV) or human herpesvirus-8 (HHV-8)/Kaposi’s sarcoma associated herpesvirus (KSHV).
The pathogenesis of ARLs is complex. B-cell proliferation driven by chronic antigenemia resulting in the induction of
polyclonal and ultimately monoclonal lymphoproliferation may occur in the setting of severe immunosuppression.
Keywords: Kaposi’s sarcoma, lymphomas, Epstein-Barr virus, KS-associated herpesvirus, human herpesvirus 8.

squamous cell carcinomas, plasmacytomas, and leiomyosarcoma in children. These tumors arose due to
the lack of appropriate immune response or the reactivation of etiological agents associate with these tumors in immunosuppressed HIV infected individuals.
Serveral AIDS-associated malignancies were found to
be associated with the viral infections. Among them,
Epstein-Barr virus (EBV) was found to associate with
NHL, HD, and leiomyosarcoma; Kaposi’s sarcoma associated herpesvirus (KSHV) or human herpesvirus-8
(HHV-8) was found to associate with KS and primary
effusion lymphoma (PEL), and human papilloma virus (HPV) was found to associate with squamous cell
neoplasia. The most common malignancies seen in
HIV-infected individuals are KS and HNL, and both
have been classified as AIDS defining illnesses.

Introduction
It has been over twenty years since the onset of the
AIDS epidemic, and in spite of the tremendous progress made towards the understanding of the disease,
the virus that causes the disease and the development
of highly effective anti-retroviral treatments, the number of people infected by HIV is still staggering. As
of the end of 2004, it was estimated that there were
39.4 million people newly infected with HIV, and 3.1
million deaths globally (www.UNAIDS.org). Over
2/3 of infections occur in the developing world and
sub-Saharan Africa. Concurrent with immunosuppression in the infected individuals are opportunistic infections and AIDS-associated diseases, including malignancies, which have increased substantially
during the AIDS disease course [1, 2]. Malignancies
that were found to have high incidence of HIV-infected individuals are Kaposi’s sarcoma (KS), Hodgkin’s disease (HD), non-Hodgkin’s lymphoma (NHL),
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decreased in developed nations where potent antiretrovirals (ARV) are widely available. However, the
prolonged survival of many HIV carriers is likely to
eventually result in an increased number of malignancies diagnosed in these individuals. Chronically immunocompromised patients have a markedly increased
risk of developing lymphoproliferative disease. The
incidence of non-Hodgkin’s lymphomas (NHL) is increased nearly 200 fold in HIV-positive patients and
accounts for a greater percentage of AIDS defining illness in the US since the advent of HAART therapy [3,
4]. AIDS related lymphomas (ARLs) are distinct from
their counterparts seen in HIV seronegative patients.
For example nearly half of all cases of ARL are associated with the presence of a gamma herpesvirus, EBV
or HHV-8 [5]. ARLs are often diagnosed at a very advanced stage and frequently involve uncommon sites
(oral cavity, GI tract, central nervous system) [5, 6]. The
pathogenesis of ARLs is complex. B-cell proliferation
driven by chronic antigenemia results in the induction
of polyclonal, and ultimately monoclonal lymphoproliferation. In addition, dysregulation of cytokine pathways (interleukin-6 and interleukin-l0), coupled with
bcl-6, p53, and c-myc mutations have been implicated
in the pathogenesis of ARL [7].
Subtypes of AIDS NHLS
AIDS NHLs may be broadly categorized into several
subtypes. Large cell immunoblastic lymphoma (IBL)
and diffuse large cell lymphoma (DLCL) generally occur inthe setting of moderate to severe immunosuppression (CD4+ lymphocyte counts below 100 mm3/
ml). IBLs and, to a lesser degree, DLCLs are often associated with EBV. These tumors express the EBV encoded oncoprotein latent membrane protein-l (LMP-l)
[5-7]. LMP-l may function in a similar manner to tumor necrosis factor receptors by activating cellular
anti-apoptotic factors such as Nuclear Factor Kappa B
[6, 7]. DLCLs are frequently found to contain genetic
alterations in Bcl-6 [8] although the consequences of
these mutations have not been fully defined.
AIDS related Burkitt’s lymphoma (BL) generally occurs in more immunocompetent patients [9]. AIDS
BLs share features with endemic African BL in that
both overexpress c-myc due to reciprocal translocations that bring the transactivator under the influence of potent promoter sequences within the immunoglobulin (Ig) genes loci. Inactivating mutations and
deletions of p53 are also common as in all types of BL
[10]. A distinguishing feature between AIDS related
and endemic BL is that the former is associated with
EBV far less frequently than the latter [9, 10]. These
tumors are incredibly aggressive with brief doubling
times. Flow cytometric analysis typically reveals that
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over 90% are in S phase. Ongoing tumor lysis syndrome even in the absence of concomitant chemotherapyis often noted. AIDS related BLs appear to carry a
poor prognosis even when compared to AIDS related
DLCL [11].
A recently described variant of ARL, plasmablastic
lymphoma, occurs in a small percent of HIV+ patients.
These tumors are generally associated with EBV and
HHV8 (10). Response to conventional chemotherapy
is poor and some investigators have suggested that viral targeted approaches may be beneficial [12].
A rapidly fatal subtype of AIDS NHL is Primary
Central Nervous System Lymphoma (PCNSL). These
tumors aremost frequently classified as IBLs and occur in the most immunosuppressed patients. In contrast to PCNSL in HIV-negative patients they are virtually always associated with EBV [13]. Detection of
EBV sequences in the CSF by polymerase chain reaction (PCR) coupled with positive Thallium spectroscopy has proven to be a helpful diagnostic tool [14].
These patients are often afflicted by many complications of HIV infection. Standard therapy with conventional chemotherapy combined with radiation therapy
results in only about a 4 month survival although long
term remission has been reported in patients treated
with high dose Zidovudine and Ganciclovir [15, 16].
The most commonly identified virus associated with
AIDS related lymphomas is EBV and there is a large
body of published work on the oncogenic mechanisms
of this agent [17, 18]. B-lymphocytes transformed by
EBV (lymphoblastoid cell lines) in vitro express an array of virus-encoded proteins including six EBV nuclear antigens (EBNAs) and three LMPs. EBNAs are
generated from differential splicing of a transcript
that arises from one of two promoters (Cp or Wp) [18].
This form of latency is termed Latency III. This form
of latency is common inimmunoblastic lymphomas
[17]. A Type II form of latency where EBNA 1, LMP-l
and LMP-2a are expressed has been identified in some
EBV associated lymphomas. In Latency I (typical of
Burkitt lymphomas) only EBNA-l (generated from the
Qp promoter) and EBERs are expressed [17, 18]. Recent studies have indicated that some heterogeneity in
EBV gene expression and EBNA promoter usage exists among endemic BL [19].
Therapy of AIDS NHL
Treatment of the AIDS NHL remains disappointing.
Polychemotherapy regimens have produced similar results although regimens that combine potent antiretrovirals with conventional chemotherapy may prove superior [20]. HIV-positive patients often have poor bone
marrow reserve which compromises the ability to deliver full dose chemotherapy. Concomitant opportu-
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nistic infections may also lead to a decrease in chemotherapy delivery. In general, response and survival
rates for common NHL regimens are lower than for
an HIV-negative population. Complete responses occur but tend to be of shorter duration with frequent relapses. Our experience has been that patients concomitantly diagnosed with HIV infection and lymphomas
do better with antiretroviral and anti-lymphoma therapy than do those who develop lymphoma after becoming refractory to antiretrovirals. A recently completed study performed by the NCI-sponsored AIDS
malignancy consortium (AMe) demonstrated the feasibility of concomitant chemotherapy with HAART [21].
Probably the best reported results for chemotherapy in
AIDS NHL were from Dr. Little’s group at the National
Cancer Institute. Using the EPOCH regimen, the group
achieved remission in 22 of 24 patients with a progression free survival of 23 months. These patients had favorable prognostic factors (median CD4+ lymphocyte
count of 233 mm3/ml) [20]. Enhanced toxicity of rituximab and CHOP chemotherapy was recently noted in a
large multi-center trial conducted by the AMC [22]. The
addition of rituximab to standard-dose CHOP as compared to CHOP alone led to increased infectious complications and deaths attributable to sepsis. It ispossible
that delayed recovery of humoral immunity could contribute to this increased risk of life-threatening bacterial
infections in HIV-infected patients. There have been
several reports on the feasibility and efficacy of high
dose chemotherapy and autologous stem cell transplant for ARL [23, 24]. It is reasonable to assume that patients with well controlled HIV and good performance
status should be considered candidates for this therapy. Newer approaches that may benefit patients with
ARL include EBV specific cytotoxic T cells and agents
that activate the lytic program of gamma herpesviruses
thereby sensitizing the tumors to antivirals [25, 26].
Kaposi’s Sarcoma
Kaposi’s sarcoma was first described by Moritz Kaposi in 1872 in several cases of multi-focal pigmented
sarcoma in elderly Mediterranean men. There are four
forms of KS. The first is known as the classic KS or sporadic KS. They are mainly found in the elderly male
population in Mediterranean countries, such as Italy
[28]. The lesions tend to be found in the lower extremities and are generally non-aggressive. The second
type is known as the endemic African KS; it is more
aggressive than the classic KS and can also involve the
lymph nodes. This form of KS was seen in the African
continent prior to the HIV epidemic and was found in
adults (both male and female) and in children [29]. The
third is the iatrogenic form of KS, which normally occurs after transplantation in patients treatedwith im-
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munosuppressive medication. This form of KS seems
to vary in geographical prevalence, and is more common in individuals of Mediterranean descent [30].
The fourth form of KS is the AIDS-KS. This is a very
aggressive type of KS, first described in early 1980’s
in homosexual men [31]. AIDS-KS not only involves
skin, but also the lymph nodes and often disseminates to lungs, gastrointestinal tract, liver, and spleen.
KS is composed of a mixture of irregular shaped,
round capillaries, and slit-like endothelium-lined
vascular spacesand spindle-shape cells with infiltrating mononuclear cells. It is not clear whether KS
represents a clonal neoplasticprocess or a polyclonal
inflammatory lesion. Studies have shown that varying
monclonality, oligoclonality, and polyclonality from
lesions of various patients [32]. The origin of the KS
spindle cells is also not clear; it has been suggested that
KS cells represent a heterogeneous populationof cells,
arising from a pluripotent mesenchmal precursor cells,
and may be of lymphatic endothelial cell origin [33].
Human Herpesvirus and KS
An infectious agent has long been suspected in the
development of KS; herpesvirus-like particles were
found in short-term KS tissue culture, and were subsequently identified as cytomegalovirus [34], but the
involvement of CMV in KS has not been confirmed.
In 1994, a novel humanherpesvirus was identified by
Chang and Moore [35] using representational difference analyses. This virus is now known as KSHV or
HHV-8, it is found to be necessary but not sufficient for
the development of all types of KS. It is clear that other
co-factors, such as immunosuppression, are required
for KS development. KSHV is found in all KS lesions,
and is mainly located in the vascular endothelial cells
and perivascular spindle-shaped cells [36]. KSHV infection is not commonly found in low-risk population but found commonly in individuals at risk for KS.
KSHV belongs to the γ-herpesvirus family, which canfurther be divided into two subgroups, y-l or lymphocrytovirus and γ-2 or rhadinovirus. EBV is the prototype
of γ-l virus and the simian herpesvirus saimini isthe
prototype of γ-2 herpesvirus [37]. KSHV is classified as
a γ-2 rhadinovirus and is the first human virus of this
subfamily identified. Like other herpesviruses, HHV-8
is a double-stranded deoxyribonucleic acid (DNA) virus. Its genome is linear, is about 165 kbp in length, and
containsat least 87 viral genes. A feature of some DNA
viruses, particularly of herpesviruses and KSHV, is the
ability of these viruses to incorporate or pirate host genes
into their genome: these genes can then play a role in
the replication, survival, and transformation functions
of the virus. KSHV was found to encode human homologue genes that regulate cell cycling like cyclin D,
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growth factors like interleukin 6, or genes that may prevent programmed cell death such as bcl-2. Deciphering
the functions of these viral genes will lead to a better
understanding of viral pathogenesis and oncogenesis.
Unlike most other herpesviruses, KSHV infection
does not seem to be widely distributed in most populations. The detection of KSHV infection relies on the
presence of antibodies against either lytic and/or latent antigens and varies among the different tests that
were used in different seroprevalence studies. In general, the frequency of infection appears to be low in
North America, certain Asian countries, and in Northern European nations such as the United Kingdom
and Germany, with most studies reporting a seroprevalence rate in normal blood donors of less than
5% [2, 38-40]. In these countries the seroprevalence of
KSHV in different risk groups mirrors the incidence
of AIDS KS, with a seroprevalence rate ofbetween
25-50% among homosexual men. In other countries
such as Italy, Greece, and Israel, especially Southern Italy, the infection rate seems to be much higher
in the general population, and is more variable, ranging between 5-35%. In contrast to North America and
Europe, KSHV infection is widespread in the African continent. High seroprevalence rates between 40
to 50% have been found in Central, West, as well as
South Africa [41-44]. Therefore, KSHV seroprevalence
tracks very closely with KS, with the highest infection rate in geographic areas where classic or endemic
forms of KS are more common. KS has a particularly
high incidence in Central African countries like the
Republic of Congo, Uganda, and Zambia; these countries also have the highest KSHV infection rates in the
world [42]. Very little is known about KSHV infection
in China even though EBV infection was found to be
ubiquitous. There were only two reported studies in
China; the study by Dilnur et al. [45] found that KSHV
was associated with KS in China. The study by Du et al.
[46] in the outskirts of China in the Xinjiang autonomy
region, where there is a high incidence of HIV-1 infection, showed that there was a high HHV-8 infection
rate. The study found KSHV infection varied among
individuals of different racial origin, it was highest in
the Khalkhas population at about 48% and lowest in
the Kazak and Han population at over 12%, but the
specimens were screened without dilution and the reproducibility of the assay was not determined, and
theprevalence among different risk groups was not
studied. Thus, there is a need to perform a systematic
comparison of risk groups using established assays.
Primary Effusion Lymphomas
In addition to KS, KSHV has also been associated with
several other AIDS-associated neoplasms, primary ef-
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fusion lymphomas, and multi-centric Castleman’s disease. Primary effusion lymphoma (PEL) was first identified as a subset of body-cavity-based lymphomas,
which subsequently was called PELs [47]. PELs are
unique as they were found to contain KSHV DNA are
most frequently found in men and in AIDS patients.
This type of lymphoma is distinguished from others
as having a distinctive morphology, bridging large
cell immunoblastic lymphoma and anaplastic large
cell lymphoma. PELs often present as lymphomatous
effusions in the pleural, peritoneal, and/or pericardial
cavity. These cells are usually CD20 negative but often
express CD45 marker but lack B-cell-associated antigens. PELs are B cell origin with clonal immunoglobulin gene rearrangements. Most PELs are co-infected
with EBV and lack e-myc gene rearrangements. PELs
are extremely rare tumors, and estimated to be about
0.13% of all AIDS-related malignancies in AIDS patients in the US [48]. Thus, KSHV-associated lymphomas represent a rare, distinct pathobiologic category
which often, but not always, associates with an effusion in AIDS patients. The role of KSHV in the development of these lymphomas is not clear since this type
of malignancy is still rare even in the populations with
high KSHV seroprevalence rate. However, KSHV has
always been found in these lymphomas, suggesting
that this virus is necessary, but other factors must be
needed for the development of PELs. These factors
could be EBV infection and/or immunosuppression.
Recently solid tumor variants with plasmablastic features have been reported and these tumors tend to be
rapidly fatal although recent data suggests that some
PEL lines are quite sensitive to inhibition of NF-KB [49].
Multi-centric Castleman’s Disease
Multi-centric Castleman’s disease (MCD) has also
been associated with KSHV infection. MCD is a rare
and poorly understood B cell lymphoproliferative disorder with vascular proliferation in the germinal centers, and is though to be related to immune dysregulation [50]. KSHV is found in almost all cases of MCD
in AIDS patients and in about 50% of cases of MCD in
HIV-negative individuals, suggesting that there is an
association between KSHV and MCD at least in HIVpositive cases [51]. However, the role of KSHV in the
pathobiology of MCD is not well understood, and it is
not clear whether there are any clinical differences between those with and without KSHV.
Impact of HAART on KS
Since the beginning of the AIDS epidemic in the early
1980’s, AIDS-KS has become one of the most common
AIDS-associated malignancies with HIV-infected homosexual males at the highest risk, and those with
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AIDS had a 50% lifetime rate of developing KS early in
the HIV epidemic [52]. However, the rate of AIDS-KS
has since steadily declined both in the US and Europe
[53]. It has been suggested that the disease may have
shifted from an early disease to a late manifestation
during the HIV disease course. Since the introduction
of highly active antiretroviral therapy, a further major
decrease in AIDS-KS was further observed [54], and
therapy has now made AIDS-KS a relatively rare tumor in treated HIV-infected individuals [55]. Several
studies have shown that there was a marked decrease
in KS incidence since HAART was introduced, a decline of as high as 80-fold was observed. In addition regression of KS following treatment has been reported
[4, 56-59]. Interestingly, the reduced KS risk was only
observed with HAART, but not with double or single
anti-HIVdrugs [60]. Even though the incidence of KS
in the treated HIV-infected individuals in the western
world has decreased dramatically, in the setting where
HAART is still not widely available, such as sub-Saharan Africa, AIDS-KS still remains a major problem.
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